A PAI-1 Mutant, PAI-1R, Slows Progression of Diabetic Nephropathy

Overview

Journal J Am Soc Nephrol

Specialty Nephrology

Date 2008 Jan 25

PMID 18216319

Citations 52

Authors

Yufeng Huang

Wayne A Border

Ling Yu

Jiandong Zhang

Daniel A Lawrence

Nancy A Noble

Affiliations

Soon will be listed here.

Abstract

Plasminogen activator inhibitor-1 (PAI-1) has been implicated in renal fibrosis. In vitro, PAI-1 inhibits plasmin generation, and this decreases mesangial extracellular matrix turnover. PAI-1R, a mutant PAI-1, increases glomerular plasmin generation, reverses PAI-1 inhibition of matrix degradation, and reduces disease in experimental glomerulonephritis. This study sought to determine whether short-term administration of PAI-1R could slow the progression of glomerulosclerosis in the db/db mouse, a model of type 2 diabetes in which mesangial matrix accumulation is evident by 20 wk of age. Untreated uninephrectomized db/db mice developed progressive albuminuria and mesangial matrix expansion between weeks 20 and 22, associated with increased renal mRNA encoding alpha1(I) and (IV) collagens and fibronectin. Treatment with PAI-1R prevented these changes without affecting body weight, blood glucose, glycosylated hemoglobin, creatinine, or creatinine clearance; therefore, PAI-1R may prevent progression of glomerulosclerosis in type 2 diabetes.

Citing Articles

Repurposing Niclosamide to Modulate Renal RNA-Binding Protein HuR for the Treatment of Diabetic Nephropathy in db/db Mice.

Zhuang L, Liu W, Tsai X, Outtrim C, Tang A, Wang Z Int J Mol Sci. 2024; 25(17).

PMID: 39273597 PMC: 11394915. DOI: 10.3390/ijms25179651.

Engineered Bone Marrow Stem Cell-Sheets Alleviate Renal Damage in a Rat Chronic Glomerulonephritis Model.

Wang B, Kim K, Tian M, Kameishi S, Zhuang L, Okano T Int J Mol Sci. 2023; 24(4).

PMID: 36835123 PMC: 9959772. DOI: 10.3390/ijms24043711.

A novel peptide ligand-coated nano-siRNA-lipoplex technology for kidney targeted gene therapy.

Liu X, Zhang J, Tang A, Xu L, Huang Y Am J Transl Res. 2022; 14(10):7362-7377.

PMID: 36398217 PMC: 9641478.

The role of CDH2 and MCP-1 mRNAs of blood extracellular vesicles in predicting early-stage diabetic nephropathy.

Dehghanbanadaki H, Forouzanfar K, Kakaei A, Zeidi S, Salehi N, Arjmand B PLoS One. 2022; 17(4):e0265619.

PMID: 35363774 PMC: 8975111. DOI: 10.1371/journal.pone.0265619.

Abnormal Blood Coagulation and Kidney Damage in Aged Hamsters Infected with Severe Acute Respiratory Syndrome Coronavirus 2.

Ohno M, Sasaki M, Orba Y, Sekiya T, Masum M, Ichii O Viruses. 2021; 13(11).

PMID: 34834944 PMC: 8618556. DOI: 10.3390/v13112137.

References

Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens R, Yu L . Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 2005; 69(1):105-13. DOI: 10.1038/sj.ki.5000011. View

FISHER E, McLennan S, Yue D, Turtle J . High glucose reduces generation of plasmin activity by mesangial cells. Microvasc Res. 1997; 53(2):173-8. DOI: 10.1006/mvre.1996.2006. View

Mignatti P . Extracellular matrix remodeling by metalloproteinases and plasminogen activators. Kidney Int Suppl. 1995; 49:S12-4. View

Geiger M, Binder B . Plasminogen activation in diabetes mellitus. Kinetics of plasmin formation with tissue plasminogen activator and plasminogen from individual diabetic donors and with in vitro glucosylated plasminogen. Enzyme. 1988; 40(2-3):149-57. View

Parving H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P . The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 345(12):870-8. DOI: 10.1056/NEJMoa011489. View

Brenner B, Garcia D, Anderson S . Glomeruli and blood pressure. Less of one, more the other?. Am J Hypertens. 1988; 1(4 Pt 1):335-47. DOI: 10.1093/ajh/1.4.335. View

Yu L, Border W, Anderson I, McCourt M, Huang Y, Noble N . Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney Int. 2004; 66(5):1774-84. DOI: 10.1111/j.1523-1755.2004.00901.x. View

Gilbert R, Cox A, Dziadek M, Cooper M, Jerums G . Extracellular matrix and its interactions in the diabetic kidney: a molecular biological approach. J Diabetes Complications. 1995; 9(4):252-4. DOI: 10.1016/1056-8727(95)80015-7. View

Cheng Q, ORIKASA M, Morioka T, Kawachi H, Chen X, Oite T . Progressive renal lesions induced by administration of monoclonal antibody 1-22-3 to unilaterally nephrectomized rats. Clin Exp Immunol. 1995; 102(1):181-5. PMC: 1553319. DOI: 10.1111/j.1365-2249.1995.tb06653.x. View

10.

Steffes M, Osterby R, Chavers B, MAUER S . Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes. 1989; 38(9):1077-81. DOI: 10.2337/diab.38.9.1077. View

11.

Keller G, Zimmer G, Mall G, Ritz E, Amann K . Nephron number in patients with primary hypertension. N Engl J Med. 2003; 348(2):101-8. DOI: 10.1056/NEJMoa020549. View

12.

Nicholas S, Aguiniga E, Ren Y, Kim J, Wong J, Govindarajan N . Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int. 2005; 67(4):1297-307. DOI: 10.1111/j.1523-1755.2005.00207.x. View

13.

Lawrence D, Palaniappan S, Stefansson S, Olson S, SHORE J, Ginsburg D . Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis. J Biol Chem. 1997; 272(12):7676-80. DOI: 10.1074/jbc.272.12.7676. View

14.

Hamar P, Kokeny G, Liptak P, Krtil J, Adamczak M, Amann K . The combination of ACE inhibition plus sympathetic denervation is superior to ACE inhibitor monotherapy in the rat renal ablation model. Nephron Exp Nephrol. 2007; 105(4):e124-36. DOI: 10.1159/000100494. View

15.

Rennard S, Berg R, Martin G, Foidart J, Robey P . Enzyme-linked immunoassay (ELISA) for connective tissue components. Anal Biochem. 1980; 104(1):205-14. DOI: 10.1016/0003-2697(80)90300-0. View

16.

Huang Y, Haraguchi M, Lawrence D, Border W, Yu L, Noble N . A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest. 2003; 112(3):379-88. PMC: 166295. DOI: 10.1172/JCI18038. View

17.

Sharma K, McCue P, Dunn S . Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol. 2003; 284(6):F1138-44. DOI: 10.1152/ajprenal.00315.2002. View

18.

Osterby R, Parving H, Hommel E, Jorgensen H, Lokkegaard H . Glomerular structure and function in diabetic nephropathy. Early to advanced stages. Diabetes. 1990; 39(9):1057-63. DOI: 10.2337/diab.39.9.1057. View

19.

Benigni A, Zoja C, Corna D, Zatelli C, Conti S, Campana M . Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol. 2003; 14(7):1816-24. DOI: 10.1097/01.asn.0000074238.61967.b7. View

20.

Schnaper H . Balance between matrix synthesis and degradation: a determinant of glomerulosclerosis. Pediatr Nephrol. 1995; 9(1):104-11. DOI: 10.1007/BF00858986. View